Natasha Leighl, M.D. – FDA Inspection, Nov 22, 2024

Record Details

This FDA Inspection record concerns Natasha Leighl, M.D., with an inspection on November 22, 2024, issued by the Office of Inspections and Investigations, covering human drugs.

Company: Natasha Leighl, M.D.
Inspection Date: November 22, 2024
Product Type: Human Drugs
Office: Office of Inspections and Investigations
Person: Kristin M. Abaonza (FDA Associated Person)

View Company Profile

ID · c73a951a-c06b-45e2-a16a-36b1d4d906c1

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number: 1255845
FDA center: Human Drugs
Project area: Bioresearch Monitoring: Human Drugs
Outcome: Form 483 issued

FDA Citations

21 CFR 50.20Understandable language

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Natasha Leighl, M.D.

FDA Inspection

Natasha Leighl, M.D.November 22, 2024